Merck Scores Positive Feedback From EU Regarding Cancer Drug
On Friday, a European agency adopted two positive opinions for Merck & Co. Inc.'s MRK Keytruda ( pembrolizumab ) . One opinion recommends approval of a new subcutaneous ( SC ) administration route and a solution for injection formulation.
Source: Benzinga The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments